BNDX - Vanguard Total International Bond ETF

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
54.52
-0.02 (-0.04%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close54.54
Open54.50
Bid51.24 x 100
Ask54.63 x 100
Day's Range54.46 - 54.52
52 Week Range53.84 - 55.28
Volume611,525
Avg. Volume1,140,569
Net Assets105.14B
NAV54.57
PE Ratio (TTM)N/A
Yield2.22%
YTD Return0.83%
Beta (3y)0.83
Expense Ratio (net)0.11%
Inception Date2013-05-31
Trade prices are not sourced from all markets
  • 29 days ago

    Global Bond ETF Investors Eye China Exposure

    Global bond ETF investors that track the benchmark Bloomberg Barclays Global Aggregate Index may soon have exposure to Chinese renminbi-denominated government and policy bank securities. Bloomberg announced ...

  • PR Newswire5 months ago

    BiondVax and NIH Sign Clinical Trial Agreement for a Phase 2 Trial in the U.S. with BiondVax's Universal Flu Vaccine

    BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced the signing of the clinical trial agreement (CTA) for a Phase 2 clinical trial with the National Institute of Allergy and Infectious Diseases (NIAID) of the U.S. National Institutes of Health (NIH). The study is titled "A Phase II, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial to Assess the Safety, Reactogenicity, and Immunogenicity of Two Doses of Multimeric-001 (M-001) Followed by Seasonal Trivalent Influenza Vaccine." It is designed to evaluate the cell mediated immunity directly induced by BiondVax's universal flu vaccine candidate M-001, as well as M-001's priming effect to enhance the immunogenicity of current seasonal influenza vaccines.

  • Morningstar5 months ago

    ETF Ratings Upgrades and Downgrades

    There have been few changes since we first began issuing Morningstar Analyst Ratings for ETFs one year ago, but we've ramped up coverage dramatically.

  • Market Realist6 months ago

    Why the Recent Election Results Are Positive for Japan

    Japanese Prime Minister Shinzo Abe’s call for an early election worked in his favor. He called for a snap election to take advantage of his high ratings.

  • Market Realist6 months ago

    Bank of Japan Thinks the Inflation Target Can Be Achieved by 2019

    For Japan's economy, the main struggle has been the low level of inflation. Japan's inflation has been low for the past three decades.

  • Benzinga7 months ago

    Going Overseas For Fixed Income Exposure

    When fixed income investors typically think about geography, they usually focus on U.S. bonds, whether it be Treasuries or corporate debt issued by US-based firms. Flows to exchange-traded funds confirm ...

  • Looking Overseas For Fixed Income
    ETF.com7 months ago

    Looking Overseas For Fixed Income

    How and why you should go abroad for exposure.

  • Market Realist7 months ago

    Bank of Japan Sees Rising Political Uncertainty as a Risk

    According to news reports, Japanese Prime Minister Shinzo Abe could be calling for a snap election next month to capitalize on the increased approval ratings in August.

  • Market Realist7 months ago

    Why Rising Japanese Inflation Isn’t Good Enough for Bank of Japan

    The BOJ's (Bank of Japan’s) qualitative and quantitative easing (or QQE) programs and a negative interest rate are helping to slowly revive Japanese inflation.

  • PR Newswire7 months ago

    BiondVax Announces Closing of $10 Million Public Offering of American Depositary Shares and Exercise of Over-allotment Option

    BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, announced today that it has closed an underwritten public offering of 1,500,000 American Depositary Shares ("ADS"), each ADS representing forty (40) of its ordinary shares which are listed on the Tel Aviv Stock Exchange (at NIS 0.0000001 par value each), at a price to the public of $6.00 per ADS. In connection with the public offering, the underwriters exercised in full their over-allotment option to purchase an additional 166,667 shares of common stock at the public offering price, less the underwriting discount. As a result, the total public offering size was 1,666,667 shares, and the gross proceeds from the public offering were $10 million, before deducting underwriting discounts and offering expenses.

  • PR Newswire7 months ago

    BiondVax Announces Public Offering of American Depositary Shares

    BiondVax Pharmaceuticals Ltd. (BVXV) (BVXV.TA), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced that it intends to offer for sale its American Depositary Shares ("ADS"), each representing forty (40) of its ordinary shares which are listed on the Tel Aviv Stock Exchange (at NIS 0.0000001 par value each). All of the ADSs in the offering are being offered by BiondVax. The offering is subject to market conditions and there can be no assurance as to whether the offering may be completed, or as to the actual size or terms of the offering.

  • PR Newswire8 months ago

    Dual-Listed BiondVax to Voluntarily Delist from Tel Aviv Stock Exchange

    BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), developer of the universal flu vaccine candidate M-001, today announced that its Board of Directors has decided to voluntarily delist from the Tel Aviv Stock Exchange (TASE), while maintaining a continued listing on NASDAQ. Following the European Investment Bank (EIB)'s significant €20 million funding agreement[1], and as BiondVax progresses towards Phase 3 clinical trials[2] and construction of its commercial mid-size manufacturing facility[3], the Board of Directors decided that BiondVax will focus its efforts on the international scene.

  • Market Realist8 months ago

    Will Jackson Hole in 2017 Be the Beginning of the End of Monetary Accommodation?

    This year’s theme for the annual Jackson Hole Symposium is “Fostering a Dynamic Global Economy.”

  • PR Newswire8 months ago

    BiondVax Receives Additional Grant Funding

    Israel Innovation Authority Approves Additional Budget towards M-001 Flu Vaccine Development NESS ZIONA, Israel , August 14, 2017 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) (TASE: BVXV) ...

  • PR Newswire9 months ago

    BiondVax Reports Positive Phase 2b Clinical Trial Results for its Universal Flu Vaccine

    European UNISEC Co-Sponsored Trial Meets Both Primary Endpoints NESS ZIONA, Israel , July 20, 2017 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV), and the UNISEC consortium today ...

  • PR Newswire9 months ago

    BiondVax Signs Lease Agreement for Mid-Size Commercial Facility to Manufacture Universal Flu Vaccine

    BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV), developer of the Universal Flu Vaccine candidate M-001, today signed an agreement to lease approximately 1800m2 in the Jerusalem BioPark (JBP), located in the Ein Kerem Hadassah campus, next to Hadassah University Hospitals and Hebrew University's Medical School. M-001 is designed to provide protection against current and future seasonal and pandemic flu strains. Planning and design of the facility by a leading engineering company has begun, and while construction will begin soon, the agreement calls for BiondVax to begin lease payments in October 2018.

  • The One-Flat-Fee-Fits-All ETF Strategist
    ETF.com9 months ago

    The One-Flat-Fee-Fits-All ETF Strategist

    First Ascent Asset Management is a newcomer in the ETF strategist space, building two series of portfolios for advisors: one using only ETFs, the other combining ETFs with actively managed mutual funds.

  • PR Newswire10 months ago

    BiondVax's CEO Provides First Half 2017 General Corporate Update

    BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV), developer of the Universal Flu Vaccine candidate M-001, today provided a general corporate update of its activities in the first half of 2017. Ron Babecoff, BiondVax CEO, commented, "The first half of 2017 was exciting and important for BiondVax.

  • Best Bond ETFs for 2017 and Beyond
    Motley Fool10 months ago

    Best Bond ETFs for 2017 and Beyond

    Here are five ETFs that can help you get bond exposure in your portfolio.

  • PR Newswire10 months ago

    European Investment Bank (EIB) Supports Late-Stage Development and Production of BiondVax's Universal Flu Vaccine Candidate Under Horizon 2020 Initiative

    The European Investment Bank (EIB) and BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV), developer of the Universal Flu Vaccine candidate M-001, announced that they have entered into a €20 million (approximately $22 million) loan agreement. The event organized to mark the collaboration and the granting of the loan occurs today at the EIB Headquarters in Luxembourg, in presence of Mr. Ambroise Fayolle, EIB Vice-President responsible for innovation, and Dr. Ron Babecoff, CEO of BiondVax. Flu viruses frequently and unpredictably mutate.

  • Do You Know Where Your Global Bond Money Goes?
    Harvest Exchangelast year

    Do You Know Where Your Global Bond Money Goes?

    By Erin Bigley April 25, 2017 More and more investors are globalizing their bond portfolios these days—with good reason. But when it comes to reducing risk, active management is essential. The French presidential election is just one reason. Bond ...